SC 13G | 2024-04-01 | Venrock Healthcare Capital Partners III, L.P. | Aquestive Therapeutics, Inc. | 5,555,555 | 6.5% | EDGAR |
SC 13G | 2024-02-14 | ARMISTICE CAPITAL, LLC | Aquestive Therapeutics, Inc. | 3,924,000 | 5.9% | EDGAR |
SC 13G/A | 2022-02-11 | BRATTON DOUGLAS K | Aquestive Therapeutics, Inc. | 3,468,747 | 8.6% | EDGAR |
SC 13G/A | 2021-02-16 | PERCEPTIVE ADVISORS LLC | Aquestive Therapeutics, Inc. | 1,385,720 | 4.1% | EDGAR |
SC 13G/A | 2021-02-09 | BRATTON DOUGLAS K | Aquestive Therapeutics, Inc. | 4,032,907 | 12.0% | EDGAR |
SC 13G/A | 2020-12-01 | Madryn Asset Management, LP | Aquestive Therapeutics, Inc. | 1,530,717 | 4.2% | EDGAR |
SC 13G/A | 2020-02-14 | PERCEPTIVE ADVISORS LLC | Aquestive Therapeutics, Inc. | 2,250,000 | 7.0% | EDGAR |
SC 13G/A | 2020-02-12 | BRATTON DOUGLAS K | Aquestive Therapeutics, Inc. | 4,032,907 | 16.1% | EDGAR |
SC 13G | 2019-09-09 | Madryn Asset Management, LP | Aquestive Therapeutics, Inc. | 1,428,572 | 5.5% | EDGAR |
SC 13G | 2019-02-14 | PERCEPTIVE ADVISORS LLC | Aquestive Therapeutics, Inc. | 2,113,400 | 8.5% | EDGAR |
SC 13G | 2019-02-13 | BRATTON DOUGLAS K | Aquestive Therapeutics, Inc. | 4,032,907 | 16.2% | EDGAR |